Cannabigerol against obesity: new study reveals how CBG-rich Cannabis extracts attack fat

A study recently published in International Journal of Molecular Sciences explores the anti-obesity potential of CBG (cannabigerol)-dominant Cannabis sativa extracts.

The research, entitled «Comparative anti-obesity potential of cannabigerol-dominant Cannabis sativa L. inflorescence extracts via differential regulation of lipid metabolism in 3T3-L1 cells», was conducted by scientists from Wonkwang University and collaborating institutions in South Korea. Using a widely recognized laboratory model of fat cell development, the team investigated how extracts rich in cannabigerol (CBG) affect the molecular pathways linked to obesity.

Although the findings remain limited to in vitro conditions, the results suggest that the CBG-dominant extracts could regulate fat cell formation, lipid storage and energy expenditure through several complementary mechanisms.

Obesity and the search for multi-target therapies

Obesity is a chronic metabolic disorder characterized by an excessive accumulation of fat and closely associated with type 2 diabetes, hypertension and cardiovascular disease. Existing pharmacological strategies, such as CB1 receptors or GLP-1 receptor agonists, can be effective, but are often accompanied by significant side effects or high costs.

In this context, researchers are increasingly interested in plant-derived compounds capable of simultaneously targeting several metabolic pathways. The Cannabis sativa contains a wide range of bioactive molecules, including major cannabinoids such as CBD and THC, as well as minor compounds such as CBG, the CBC and the CBN.

If the CBD has already been studied for its potential role in reducing lipogenesis and promoting lipolysis. metabolic effects of CBG are much less well known. The new study attempts to fill this gap.

Four extracts, one dominant cannabinoid

The researchers prepared four extracts from’Cannabis sativa inflorescences with CBG dominance, using ethanol at concentrations of 30 %, 50 %, 70 % and 99.5 %. These were labelled CE30, CE50, CE70 and CE99.5.

Chemical analysis by UPLC confirmed the presence of seven cannabinoids, including CBG and its CBGA acid precursor as the predominant constituents. Cannabichromene (CBC) was also detected. It should be noted that total CBG concentration increased in parallel with ethanol concentration, peaking in the 99.5 % ethanol extract.

This correlation proved important: the extract containing the highest concentration of cannabinoids, CE99.5, consistently showed the highest biological activity in subsequent experiments.

Blocking fat cell differentiation

To assess anti-obesity activity, the team used the 3T3-L1 cell line, a standard in vitro model for studying adipocyte differentiation. These pre-adipocytes can be induced to mature into fat-storing cells, mimicking key aspects of adipogenesis.

In all four extracts, the researchers observed a dose-dependent inhibition of fat cell differentiation. Staining with Oil Red O, which measures lipid accumulation, revealed that CE99.5 achieved the greatest suppression, inhibiting differentiation by up to 62 % at the concentrations tested.

Importantly, cell viability remained above 90 % at most concentrations for CE30, CE50 and CE70, while CE99.5 maintained acceptable viability at moderate doses. This suggests that the inhibitory effect was not simply due to cytotoxicity.

Down-regulation of adipogenesis and lipogenesis

At the molecular level, the extracts significantly reduced the expression of key markers of adipogenesis and lipogenesis.

Genes such as PPARγ and C/EBPα, the main regulators of adipocyte formation, were markedly down-regulated after treatment, particularly with CE99.5. Similarly, lipogenic factors, notably SREBP-1c and FAS, which govern the synthesis of fatty acids, have been considerably suppressed.

Protein analysis confirmed these results. In some cases, CE99.5 reduced adipogenic protein expression by more than 80 % compared with untreated differentiated cells.

Collectively, these results indicate that CBG-dominant Cannabis sativa extracts can interfere with both the formation of new fat cells and the synthesis of lipids within them.

Stimulates lipolysis and browning of white fat

In addition to inhibiting fat formation, the study also examined whether the extracts could improve lipid breakdown and energy expenditure.

Lipolytic enzymes HSL (hormone-sensitive lipase) and ATGL (adipose triglyceride lipase), which are essential for triglyceride breakdown, were significantly up-regulated after treatment. In CE99.5-treated cells, ATGL protein levels increased up to 11.7-fold compared to differentiated controls.

The extracts also increased markers associated with browning of white adipose tissue, including’UCP1 and the PGC-1α. Browning refers to the process by which white fat cells adopt the characteristics of brown fat cells, becoming more metabolically active and capable of dissipating energy in the form of heat.

In the highest-performing extract, UCP1 protein levels increased by a factor of almost nine. According to the authors, this dual action - reducing lipid accumulation while enhancing lipid utilization and thermogenesis - suggests a «multi-targeted» metabolic profile.

The role of cannabigerol and the entourage effect

Although the extracts contain several cannabinoids, the researchers emphasize the central role of CBG as the dominant constituent. They also refer to the concept of’ entourage effect »In this context, it is important to note that the "cannabinoids" and "terpenoids" interact synergistically to produce broader pharmacological results.

Previous research has suggested the involvement of CBG in metabolic regulation and insulin resistance, but in-depth mechanistic studies have been limited. This new work supports the idea that CBG-dominant formulations can influence lipid metabolism through coordinated modulation of adipogenesis, lipogenesis, lipolysis and thermogenic pathways.

However, the authors are careful to note that the extract represents a complex mixture. The specific contribution of each minor cannabinoid remains to be clarified by further research involving isolated compounds.

Limits of in vitro evidence

Despite promising results, the study remains limited to cell culture experiments. The 3T3-L1 model is widely used to study adipocyte biology, but it cannot reproduce the complexity of whole-organism metabolism.

The researchers acknowledge that further in vivo studies are needed to assess long-term safety, pharmacokinetics and actual metabolic outcomes. Questions also remain regarding optimal dosage, bioavailability and potential interactions with other metabolic pathways.

Nonetheless, these results help to enrich the scientific literature devoted to the study of non-intoxicating cannabinoids other than CBD, particularly in the context of metabolic health.

A new direction for cannabinoid research?

While the’interest in minor cannabinoids studies such as this one highlight the ways in which Cannabis sativa extracts can act simultaneously on several biological targets. Although clinical transposition is far from established, the data suggest that CBG-rich extracts could represent a new avenue of research in the field of obesity.

For the cannabis sector, the implications at this stage are largely scientific rather than commercial. The study does not endorse specific products or therapeutic claims, nor does it suggest any immediate clinical application.

But mapping the way cannabigerol-dominant extracts interact with fundamental lipid metabolic pathways, the research provides a basis for future investigations, which may ultimately clarify whether minor cannabinoids can play a role in the management of metabolic diseases.

For the time being, under laboratory conditions, CBG-rich Cannabis sativa extracts have demonstrated measurable and positive effects. multipathways on the biology of fat cells.

Researchers have tested an extract of Cannabis sativa rich in cannabigerol (CBG) to determine whether it could have an effect on obesity-related fat cells.

They used a laboratory model of mouse fat cells (called 3T3-L1 cells) that can transform into mature fat-storing cells. The aim was to determine whether CBG-rich extracts could :

• Reduce the formation of new fat cells
• Reduce fat storage
• Increase fat breakdown
• Increase energy combustion

What they discovered

1. Less fat cell formationCBG-rich extracts slowed down the process by which immature cells transform into fat cells.
2. Less fat productionThe extracts reduced the activity of genes that control fat creation and storage.
3. Increase fat breakdown At the same time, the extracts increased the activity of enzymes that break down stored fat.
4. Increase «energy combustion» activity» The treatment also increased markers linked to fat cell «browning», a process that causes fat tissue to burn more energy instead of storing it.

Stronger extract, stronger effect

The extract made with the highest concentration of ethanol contained the most cannabinoids and showed the most powerful effects.

Important limit

This study was carried out on laboratory cells only, and not on animals or human beings. This means we don't yet know whether the same effects would occur in the human body, or whether this treatment would be safe and effective for weight management.

Conclusion

In simple terms, the study suggests that CBG-rich Cannabis sativa extracts can reduce fat formation and increase fat burning in laboratory-grown fat cells. But much more research is needed before any conclusions can be drawn about real-world use.